Answers are grounded in this paper and cite their sources.
Decision-making process identifies considerations for applying nucleic acid test in plasma fractionation, suggesting implications for blood operators.
Highlights The study uses a simple decision tree approach to study how a parvovirus B19 (B19V) and hepatitis A virus (HAV) nucleic acid test (NAT) might be implemented to qualify plasma for fractionation. The study identifies caveats that other blood operators may need to consider when assessing whether to implement a B19V/HAV NAT assay.
No takes yet. Share an insight, caveat, or question.
Bruneau et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: